Transdermal Delivery of Vaccines and Therapeutic Proteins - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Transdermal Delivery of Vaccines and Therapeutic Proteins
The author reviews advances in technology that may soon allow transdermal delivery of two of the fastest growing drug classes on the pharmaceutical market. This article is part of a special Drug Delivery issue.


Pharmaceutical Technology
pp. s14-s20

41. K. J. Hansen et al., "Transdermal Delivery of Vaccines and Proteins using a Hand-Applied, Polymeric Microstructured Array," presented at the Controlled Release Society, Portland, OR, July 12, 2010.

42. A. V. Badkar et al., Pharm. Res. 24 (7), 1389–1395 (2007).

43. M. Pearton et al., Pharm. Res. 25 (2), 407–416 (2007).

44. G. Levin et al., Pharm. Res. 22 (4), 550–555 (2005).

45. M. Ameri, S. C. Fan, and Y. F. Maa, Pharm. Res. 27 (2), 303–313 (2010).

46. F. Cosman et al., Jrnl. Clin. Endocrinol. Metab. 95 (1), 151–158 (2010).

47. A. K. Andrianov et al., Proc. Natl. Acad. Sci. 106 (45), 18936–18941 (2009).

48. Q. Zhu et al., Proc. Natl. Acad. Sci. 106 (19), 7968–7973 (2009).

49. K. J. Hansen and B. Haldin, Drug Deliv. Technol. 8 (8), 38–42 (2008).

50 H. S. Gill, and M. R. Prausnitz, Jrnl. Control. Rel. 117 (2), 227–237 (2007).

51 P. E. Laurent et al., Vaccine 25 (52), 8833–8842 (2007).

52… I. Leroux-Roels et al., Vaccine 26 (51), 6614–6619 (2008).

53. J. Beran et al., BMC Med. 7 (13), (2009).

54. P. Van Damme et al., Vaccine 27 (3), 454–459 (2009).

55. N. Roxhed et al., IEEE Trans. Biomed. Eng. 55 (3), 1063–1071 (2008).

56. S. A. Burton et al., Pharm. Res. (July 2010), http://www.springerlink.com/content/v33v3x4850877668/, accessed Oct. 13, 2010.

57. K. J. Hansen, S. A. Burton, and M. A. Tomai, Drug Deliv. Technol. 55 (8), 38–44 (2009).

58. K. J. Hansen, S. A. Burton, and T. A. Peterson, "Transdermal Delivery of Large Molecules through an Integrated Hollow Microneedle Device," presented at the Controlled release Society, Copenhagen, Denmark, July 2009.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here